Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LeukoNorm CytoChemia
- Development stage
- Unknown
- Lead developer
- CytoChemia
- Administration
- Parenteral
01
Overview
LeukoNorm CytoChemia is a biologic, blood-derived product consisting of a leukocyte ultrafiltrate obtained from donor whole blood. Developed by CYTOCHEMIA AG, it acts as an immunomodulator designed to support embryo implantation and pregnancy maintenance by modulating the maternal immune system. It was previously approved in Germany for the treatment of immunologically-based recurrent spontaneous abortions (RSA) and has been investigated in Phase III clinical trials as a supportive immunotherapy for women experiencing repetitive implantation failures during IVF/ICSI procedures.
- Brand names
- LeukoNorm CytoChemiaLeukoNorm
- Other names
- Leukozytenultrafiltratleukocyte ultrafiltrate
Beyond the preview
Go deeper on LeukoNorm CytoChemia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LeukoNorm CytoChemia.